Tempest Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Tempest Therapeutics Inc TPST.O is expected to show no change in quarterly revenue when it reports results on November 13 (estimated) for the period ending September 30 2026
LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of 32 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tempest Therapeutics Inc is $7.00, about 1,770.7% above its last closing price of $0.37
This summary was machine generated November 11 at 13:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)